MARKET INTRODUCTION
Metabolic diseases include a complex collection of multifactorial disorders that share a common origin and targets metabolic action. The adoption of the modern lifestyle is widely associated with molecular diseases. The developments in molecular biology have resulted in various effective therapeutic techniques that enhance the life quality of people across the world.
MARKET DYNAMICS
The metabolic disorders therapeutics market growth is expected to grow faster due to increasing prevalence of metabolic disorders such as diabetes, and obesity. The growth of market is also determined due to growing market consolidations among public and private organizations and growing government support for therapeutic development. The market is expected to have growth opportunities due to growing biotechnology sector in the developing regions.
MARKET SCOPE
The "Metabolic Disorders Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of metabolic disorders therapeutics market with detailed market segmentation by type, indication, and rout of administration. The metabolic disorders therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in metabolic disorders therapeutics market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The metabolic disorders therapeutics market is segmented on the basis of type, indication, and rout of administration. Based on type, the market is divided into gene therapy, drug therapy, enzyme replacement therapy, cellular transplantation, small molecule based therapy, and substrate reduction therapy. Based on indication, the market is classified as lysosomal storage diseases, diabetes, obesity, inherited metabolic disorders, and hypercholesterolemia. And based on route of administration, the market is classified as oral, parenteral, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the metabolic disorders therapeutics market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The metabolic disorders therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting metabolic disorders therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the metabolic disorders therapeutics market in these regions.
MARKET PLAYERS
The report covers key developments in the metabolic disorders therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from metabolic disorders therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for metabolic disorders therapeutics in the global market. Below mentioned is the list of few companies engaged in the metabolic disorders therapeutics market.
The report also includes the profiles of key players in metabolic disorders therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Amgen Inc.
- Boehringer Ingelheim
- Bristol-Myers Squibb
- AbbVie Inc.
- Sanofi
- Eli Lilly and Company
- Novo Nordisk
- Takeda Pharmaceutical Company
- Biocon
- CymaBay Therapeutics
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. PUBLISHERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Metabolic Disorders Therapeutics Market - By Type
1.3.2 Metabolic Disorders Therapeutics Market - By Indication
1.3.3 Metabolic Disorders Therapeutics Market - By Route of Administration
1.3.4 Metabolic Disorders Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. METABOLIC DISORDERS THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. METABOLIC DISORDERS THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. METABOLIC DISORDERS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. METABOLIC DISORDERS THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. METABOLIC DISORDERS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. METABOLIC DISORDERS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. GENE THERAPY
7.3.1. Overview
7.3.2. Gene Therapy Market Forecast and Analysis
7.4. DRUG THERAPY
7.4.1. Overview
7.4.2. Drug Therapy Market Forecast and Analysis
7.5. ENZYME REPLACEMENT THERAPY
7.5.1. Overview
7.5.2. Enzyme Replacement Therapy Market Forecast and Analysis
7.6. CELLULAR TRANSPLANTATION
7.6.1. Overview
7.6.2. Cellular Transplantation Market Forecast and Analysis
7.7. SMALL MOLECULE BASED THERAPY
7.7.1. Overview
7.7.2. Small Molecule Based Therapy Market Forecast and Analysis
7.8. SUBSTRATE REDUCTION THERAPY
7.8.1. Overview
7.8.2. Substrate Reduction Therapy Market Forecast and Analysis
8. METABOLIC DISORDERS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. LYSOSOMAL STORAGE DISEASES
8.3.1. Overview
8.3.2. Lysosomal Storage Diseases Market Forecast and Analysis
8.3.3. Gaucher's Diseases Market
8.3.3.1. Overview
8.3.3.2. Gaucher's Diseases Market Forecast and Analysis
8.3.4. Metachromatic Leukodystrophy Market
8.3.4.1. Overview
8.3.4.2. Metachromatic Leukodystrophy Market Forecast and Analysis
8.3.5. Hurler - Scheie Market
8.3.5.1. Overview
8.3.5.2. Hurler - Scheie Market Forecast and Analysis
8.3.6. Sanfilipo A Market
8.3.6.1. Overview
8.3.6.2. Sanfilipo A Market Forecast and Analysis
8.3.7. Others Market
8.3.7.1. Overview
8.3.7.2. Others Market Forecast and Analysis
8.4. DIABETES
8.4.1. Overview
8.4.2. Diabetes Market Forecast and Analysis
8.5. OBESITY
8.5.1. Overview
8.5.2. Obesity Market Forecast and Analysis
8.6. INHERITED METABOLIC DISORDERS
8.6.1. Overview
8.6.2. Inherited Metabolic Disorders Market Forecast and Analysis
8.7. HYPERCHOLESTEROLEMIA
8.7.1. Overview
8.7.2. Hypercholesterolemia Market Forecast and Analysis
9. METABOLIC DISORDERS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ORAL
9.3.1. Overview
9.3.2. Oral Market Forecast and Analysis
9.4. PARENTERAL
9.4.1. Overview
9.4.2. Parenteral Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. METABOLIC DISORDERS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Metabolic Disorders Therapeutics Market Overview
10.1.2 North America Metabolic Disorders Therapeutics Market Forecasts and Analysis
10.1.3 North America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Type
10.1.4 North America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Indication
10.1.5 North America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Route of Administration
10.1.6 North America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Metabolic Disorders Therapeutics Market
10.1.6.1.1 United States Metabolic Disorders Therapeutics Market by Type
10.1.6.1.2 United States Metabolic Disorders Therapeutics Market by Indication
10.1.6.1.3 United States Metabolic Disorders Therapeutics Market by Route of Administration
10.1.6.2 Canada Metabolic Disorders Therapeutics Market
10.1.6.2.1 Canada Metabolic Disorders Therapeutics Market by Type
10.1.6.2.2 Canada Metabolic Disorders Therapeutics Market by Indication
10.1.6.2.3 Canada Metabolic Disorders Therapeutics Market by Route of Administration
10.1.6.3 Mexico Metabolic Disorders Therapeutics Market
10.1.6.3.1 Mexico Metabolic Disorders Therapeutics Market by Type
10.1.6.3.2 Mexico Metabolic Disorders Therapeutics Market by Indication
10.1.6.3.3 Mexico Metabolic Disorders Therapeutics Market by Route of Administration
10.2. EUROPE
10.2.1 Europe Metabolic Disorders Therapeutics Market Overview
10.2.2 Europe Metabolic Disorders Therapeutics Market Forecasts and Analysis
10.2.3 Europe Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Type
10.2.4 Europe Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Indication
10.2.5 Europe Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Route of Administration
10.2.6 Europe Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Metabolic Disorders Therapeutics Market
10.2.6.1.1 Germany Metabolic Disorders Therapeutics Market by Type
10.2.6.1.2 Germany Metabolic Disorders Therapeutics Market by Indication
10.2.6.1.3 Germany Metabolic Disorders Therapeutics Market by Route of Administration
10.2.6.2 France Metabolic Disorders Therapeutics Market
10.2.6.2.1 France Metabolic Disorders Therapeutics Market by Type
10.2.6.2.2 France Metabolic Disorders Therapeutics Market by Indication
10.2.6.2.3 France Metabolic Disorders Therapeutics Market by Route of Administration
10.2.6.3 Italy Metabolic Disorders Therapeutics Market
10.2.6.3.1 Italy Metabolic Disorders Therapeutics Market by Type
10.2.6.3.2 Italy Metabolic Disorders Therapeutics Market by Indication
10.2.6.3.3 Italy Metabolic Disorders Therapeutics Market by Route of Administration
10.2.6.4 Spain Metabolic Disorders Therapeutics Market
10.2.6.4.1 Spain Metabolic Disorders Therapeutics Market by Type
10.2.6.4.2 Spain Metabolic Disorders Therapeutics Market by Indication
10.2.6.4.3 Spain Metabolic Disorders Therapeutics Market by Route of Administration
10.2.6.5 United Kingdom Metabolic Disorders Therapeutics Market
10.2.6.5.1 United Kingdom Metabolic Disorders Therapeutics Market by Type
10.2.6.5.2 United Kingdom Metabolic Disorders Therapeutics Market by Indication
10.2.6.5.3 United Kingdom Metabolic Disorders Therapeutics Market by Route of Administration
10.2.6.6 Rest of Europe Metabolic Disorders Therapeutics Market
10.2.6.6.1 Rest of Europe Metabolic Disorders Therapeutics Market by Type
10.2.6.6.2 Rest of Europe Metabolic Disorders Therapeutics Market by Indication
10.2.6.6.3 Rest of Europe Metabolic Disorders Therapeutics Market by Route of Administration
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Metabolic Disorders Therapeutics Market Overview
10.3.2 Asia-Pacific Metabolic Disorders Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Indication
10.3.5 Asia-Pacific Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Route of Administration
10.3.6 Asia-Pacific Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Metabolic Disorders Therapeutics Market
10.3.6.1.1 Australia Metabolic Disorders Therapeutics Market by Type
10.3.6.1.2 Australia Metabolic Disorders Therapeutics Market by Indication
10.3.6.1.3 Australia Metabolic Disorders Therapeutics Market by Route of Administration
10.3.6.2 China Metabolic Disorders Therapeutics Market
10.3.6.2.1 China Metabolic Disorders Therapeutics Market by Type
10.3.6.2.2 China Metabolic Disorders Therapeutics Market by Indication
10.3.6.2.3 China Metabolic Disorders Therapeutics Market by Route of Administration
10.3.6.3 India Metabolic Disorders Therapeutics Market
10.3.6.3.1 India Metabolic Disorders Therapeutics Market by Type
10.3.6.3.2 India Metabolic Disorders Therapeutics Market by Indication
10.3.6.3.3 India Metabolic Disorders Therapeutics Market by Route of Administration
10.3.6.4 Japan Metabolic Disorders Therapeutics Market
10.3.6.4.1 Japan Metabolic Disorders Therapeutics Market by Type
10.3.6.4.2 Japan Metabolic Disorders Therapeutics Market by Indication
10.3.6.4.3 Japan Metabolic Disorders Therapeutics Market by Route of Administration
10.3.6.5 South Korea Metabolic Disorders Therapeutics Market
10.3.6.5.1 South Korea Metabolic Disorders Therapeutics Market by Type
10.3.6.5.2 South Korea Metabolic Disorders Therapeutics Market by Indication
10.3.6.5.3 South Korea Metabolic Disorders Therapeutics Market by Route of Administration
10.3.6.6 Rest of Asia-Pacific Metabolic Disorders Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Metabolic Disorders Therapeutics Market by Type
10.3.6.6.2 Rest of Asia-Pacific Metabolic Disorders Therapeutics Market by Indication
10.3.6.6.3 Rest of Asia-Pacific Metabolic Disorders Therapeutics Market by Route of Administration
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Metabolic Disorders Therapeutics Market Overview
10.4.2 Middle East and Africa Metabolic Disorders Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Indication
10.4.5 Middle East and Africa Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Route of Administration
10.4.6 Middle East and Africa Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Metabolic Disorders Therapeutics Market
10.4.6.1.1 South Africa Metabolic Disorders Therapeutics Market by Type
10.4.6.1.2 South Africa Metabolic Disorders Therapeutics Market by Indication
10.4.6.1.3 South Africa Metabolic Disorders Therapeutics Market by Route of Administration
10.4.6.2 Saudi Arabia Metabolic Disorders Therapeutics Market
10.4.6.2.1 Saudi Arabia Metabolic Disorders Therapeutics Market by Type
10.4.6.2.2 Saudi Arabia Metabolic Disorders Therapeutics Market by Indication
10.4.6.2.3 Saudi Arabia Metabolic Disorders Therapeutics Market by Route of Administration
10.4.6.3 U.A.E Metabolic Disorders Therapeutics Market
10.4.6.3.1 U.A.E Metabolic Disorders Therapeutics Market by Type
10.4.6.3.2 U.A.E Metabolic Disorders Therapeutics Market by Indication
10.4.6.3.3 U.A.E Metabolic Disorders Therapeutics Market by Route of Administration
10.4.6.4 Rest of Middle East and Africa Metabolic Disorders Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Metabolic Disorders Therapeutics Market by Type
10.4.6.4.2 Rest of Middle East and Africa Metabolic Disorders Therapeutics Market by Indication
10.4.6.4.3 Rest of Middle East and Africa Metabolic Disorders Therapeutics Market by Route of Administration
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Metabolic Disorders Therapeutics Market Overview
10.5.2 South and Central America Metabolic Disorders Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Type
10.5.4 South and Central America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Indication
10.5.5 South and Central America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Route of Administration
10.5.6 South and Central America Metabolic Disorders Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Metabolic Disorders Therapeutics Market
10.5.6.1.1 Brazil Metabolic Disorders Therapeutics Market by Type
10.5.6.1.2 Brazil Metabolic Disorders Therapeutics Market by Indication
10.5.6.1.3 Brazil Metabolic Disorders Therapeutics Market by Route of Administration
10.5.6.2 Argentina Metabolic Disorders Therapeutics Market
10.5.6.2.1 Argentina Metabolic Disorders Therapeutics Market by Type
10.5.6.2.2 Argentina Metabolic Disorders Therapeutics Market by Indication
10.5.6.2.3 Argentina Metabolic Disorders Therapeutics Market by Route of Administration
10.5.6.3 Rest of South and Central America Metabolic Disorders Therapeutics Market
10.5.6.3.1 Rest of South and Central America Metabolic Disorders Therapeutics Market by Type
10.5.6.3.2 Rest of South and Central America Metabolic Disorders Therapeutics Market by Indication
10.5.6.3.3 Rest of South and Central America Metabolic Disorders Therapeutics Market by Route of Administration
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. METABOLIC DISORDERS THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. AMGEN INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BOEHRINGER INGELHEIM
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BRISTOL-MYERS SQUIBB
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. ABBVIE INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. SANOFI
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ELI LILLY AND COMPANY
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. NOVO NORDISK
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. TAKEDA PHARMACEUTICAL COMPANY
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. BIOCON
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. CYMABAY THERAPEUTICS
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT PUBLISHERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. Amgen Inc.
2. Boehringer Ingelheim
3. Bristol-Myers Squibb
4. AbbVie Inc.
5. Sanofi
6. Eli Lilly and Company
7. Novo Nordisk
8. Takeda Pharmaceutical Company
9. Biocon
10. CymaBay Therapeutics
Global Lucid Ganoderma P.E. Market Repor..
Research Scope
This report researches the worldwide Lucid G..
+1-646-791 7070US (Toll Free)